Roya Farhadi1, Alireza Rafiei2, Sahar Hamdamian3, Hasan Zamani4, Jamshid Yazdani5. 1. Pediatrics Department, Mazandaran University of Medical Sciences, Sari, Iran. Electronic address: dr.royafarhadi@gmail.com. 2. Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran. 3. Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. 4. Pediatrics Department, Mazandaran University of Medical Sciences, Sari, Iran. 5. Department of Biostatistics, Faculty of Health, Mazandaran University of Medical Science, Sari, Iran.
Abstract
OBJECTIVES: Pentraxin 3 is a novel biomarker produced by vascular endothelial cells and macrophages. In recent studies involving adults, pentraxin 3 has been introduced as a reliable biomarker in the evaluation of cardiovascular disease and pulmonary hypertension. This study was conducted with an aim to measure the level of pentraxin 3 in neonates with pulmonary hypertension and comparing with normal healthy controls. DESIGN AND METHODS: In a case-control study, plasma pentraxin 3 levels were evaluated in 3 groups of neonates including neonates with pulmonary arterial hypertension (PAH), neonates with congenital heart disease without pulmonary arterial hypertension (CHD-PAH) and normal healthy neonates. RESULTS: Plasma pentraxin 3 levels in 72 neonates (21 in PAH, 19 in CHD-PAH, and 32 in control group) were measured. Demographic characteristics had no significant statistical difference among the 3 groups. Pentraxin 3 levels in PAH group was significantly higher than CHD-PAH and control groups (2.12±2.32 vs. 0.58±0.57 and 1.03±1.38ng/mL, P=0.008, respectively). No significant correlation was found between concentrations of pentraxin 3 and cardiac ejection fractions between PAH and CHD-PAH (r=0.009, P=0.97). However, significant positive correlation was detected between PTX3 concentrations and pulmonary pressures between these two groups (r=0.499, P=0.001). CONCLUSIONS: Results from our study showed that pentraxin 3 levels were increased in newborn infants with pulmonary hypertension. Plasma pentraxin 3 could be considered as a novel adjunct diagnostic tool in the evaluation of pulmonary hypertension in combination with echocardiography or as a diagnostic tool when echocardiography is not readily available for confirmation of increased pulmonary pressure.
OBJECTIVES:Pentraxin 3 is a novel biomarker produced by vascular endothelial cells and macrophages. In recent studies involving adults, pentraxin 3 has been introduced as a reliable biomarker in the evaluation of cardiovascular disease and pulmonary hypertension. This study was conducted with an aim to measure the level of pentraxin 3 in neonates with pulmonary hypertension and comparing with normal healthy controls. DESIGN AND METHODS: In a case-control study, plasma pentraxin 3 levels were evaluated in 3 groups of neonates including neonates with pulmonary arterial hypertension (PAH), neonates with congenital heart disease without pulmonary arterial hypertension (CHD-PAH) and normal healthy neonates. RESULTS: Plasma pentraxin 3 levels in 72 neonates (21 in PAH, 19 in CHD-PAH, and 32 in control group) were measured. Demographic characteristics had no significant statistical difference among the 3 groups. Pentraxin 3 levels in PAH group was significantly higher than CHD-PAH and control groups (2.12±2.32 vs. 0.58±0.57 and 1.03±1.38ng/mL, P=0.008, respectively). No significant correlation was found between concentrations of pentraxin 3 and cardiac ejection fractions between PAH and CHD-PAH (r=0.009, P=0.97). However, significant positive correlation was detected between PTX3 concentrations and pulmonary pressures between these two groups (r=0.499, P=0.001). CONCLUSIONS: Results from our study showed that pentraxin 3 levels were increased in newborn infants with pulmonary hypertension. Plasma pentraxin 3 could be considered as a novel adjunct diagnostic tool in the evaluation of pulmonary hypertension in combination with echocardiography or as a diagnostic tool when echocardiography is not readily available for confirmation of increased pulmonary pressure.
Authors: Maged A El Wakeel; Rania N Sabry; Ghada M El-Kassas; Shereen A Abd El-Gaffar; Wael H El Batal; Essam M Galal; Ashraf Azmy; Eman Awadallah Journal: Open Access Maced J Med Sci Date: 2019-08-14